Targeted Radionuclide Therapy (TRT) 

Circle Oncodesign Services

Offering unique solution with Targeted Radionuclide Therapy (TRT) for better precision medicine 


As stand alone or in combination, TRT has an important role to play in the treatment of cancer patient. Oncodesign Services has the expertise and the capabilities to support the development of novel Targeted Radionuclide Therapy compounds. 


Introduction to TRT 


Targeted Radionuclide Therapy (TRT) is a type of oncology treatment that uses radioactivity to specifically target and destroy cancer cells. This approach is based on the principle of delivering radiation directly to cancer cells while minimizing damage to surrounding healthy tissues. 

Unlike external beam radiation therapy, where radiation is directed from outside the body, targeted radionuclide therapy involves the internal delivery of radiation. The radiopharmaceutical is usually administered intravenously and circulates through the bloodstream, selectively binding to cancer cells. 

Once the radiopharmaceutical has bound to the cancer cells, the radioactive decay of the radionuclide emits radiation, primarily in the form of alpha or beta particles. These particles have a short range, allowing for localized damage to the targeted cancer cells. 

Common radionuclides used in targeted radionuclide therapy include iodine-131, lutetium-177, and yttrium-90, among others. 



Using TRT in Drug Discovery research 


Targeted Radionuclide Therapy (TRT) is actively researched and used in certain cancer treatments, such as the use of lutetium-177 PSMA in the treatment of prostate cancer or iodine-131 in the treatment of thyroid cancer. It offers a promising approach for delivering more precise and effective cancer treatments with fewer side effects compared to conventional therapies. 



DRIVE-MRT : a DRug Integrative discoVEry of TRT 


Development of targeted radiotherapies requires a continuum of expertise from radiochemistry to pharmaco-imaging, integrating drug discovery process and radiotherapy clinical strategies.  

Oncodesign Services offers stand-alone (SOLO) or integrated development package (DRIVE-MRT) for Targeted Radionuclide Therapy, also known as molecular radiotherapy or radiotheranostics. This offer provides biologics engineering, research-grade and cGMP chelators, bioconjugation and in-life modeling in- as well as dosimetry analyses and radiopharmaceutical clinical trial with privileged partners.  

With these partnerships, Oncodesign Services can offer complete discovery, development and clinical packages for developers of Targeted Radionuclide Therapy (TRT). 

Get in touch